首页 | 本学科首页   官方微博 | 高级检索  
     


MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected,MAGE-A3-positive,stage III melanoma (DERMA): a double-blind,randomised, placebo-controlled,phase 3 trial
Authors:Brigitte Dreno  John F Thompson  Bernard Mark Smithers  Mario Santinami  Thomas Jouary  Ralf Gutzmer  Evgeny Levchenko  Piotr Rutkowski  Jean-Jacques Grob  Sergii Korovin  Kamil Drucis  Florent Grange  Laurent Machet  Peter Hersey  Ivana Krajsova  Alessandro Testori  Robert Conry  Bernard Guillot  John M Kirkwood
Affiliation:1. Department of Dermatooncology, Hotel Dieu Nantes University Hospital, Nantes, France;2. Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia;3. Queensland Melanoma Project, Discipline of Surgery, The University of Queensland, Princess Alexandra Hospital, Woolloongabba, QLD, Australia;4. Melanoma Sarcoma Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy;5. Service d''Oncologie Médicale, Hôpital François Mitterrand, Pau, France;6. Skin Cancer Center Hannover, Department of Dermatology, Hannover Medical School, Hannover, Germany;7. Petrov Research Institute of Oncology, St Petersburg, Russia;8. Department of Soft Tissue, Bone Sarcoma, and Melanoma, Maria Sklodowska-Curie Institute, Oncology Center, Warsaw, Poland;9. Department of Dermatology and Skin Cancers, La Timone APHM Hospital, Aix-Marseille University, Marseille, France;10. Department of Skin and Soft Tissue Tumours, National Cancer Institute, Kiev, Ukraine;11. Swissmed Centrum Zdrowia, Gdansk, Poland;12. Department of Surgical Oncology, Gdansk Medical University, Gdansk, Poland;13. Dermatology Department, Hôpital Robert Debré, Université de Reims Champagne-Ardenne, Reims, France;14. Department of Dermatology, Centre Hospitalier Universitaire, Tours, France;15. UFR de Médecine, Université François-Rabelais, Tours, France;p. Melanoma Immunology and Oncology Group, Centenary Institute, University of Sydney, Sydney, NSW, Australia;q. Melanoma Institute Australia, Sydney, NSW, Australia;r. Dermato-oncology Department, General University Hospital, Prague, Czech Republic;s. Columbus Clinic Center, Milan, Italy;t. Division of Hematology & Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA;u. Département de Dermatologie, Centre Hospitalier Universitaire, Hôpital Saint-Éloi, Montpellier, France;v. Department of Medical Oncology, Erasmus MC Cancer institute, Rotterdam, Netherlands;w. Cancer Research Center, Moscow, Russia;x. Seattle Cancer Care Alliance, University of Washington, Seattle, WA, USA;y. Department of Oncology and Medical Radiology, Dnipropetrovsk State Medical Academy, Dnipropetrovsk, Ukraine;z. Centrum Medyczne Bieńkowski, Klinika Chirurgii Plastycznej, Bydgoszcz, Poland;11. Department of Oncological Surgery, Oncology Center, Bydgoszcz, Poland;12. Melanoma Unit, Dermatology Department, Hospital Clinic of Barcelona, Institut d''Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain;13. Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III, Barcelona, Spain;14. Instituto de Oncología Ángel H Roffo, Universidad de Buenos Aires, Buenos Aires, Argentina;15. Department of Dermatology, Venereology, and Allergology, University Hospital Schleswig-Holstein, Kiel, Germany;16. Medical Statistics, Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Netherlands;17. GlaxoSmithKline, Rixensart, Belgium;18. Immunology Translational Medicine, UCB, Brussels, Belgium;19. Biostatistics Department, Janssen Research & Development, Beerse, Belgium;110. ViaNova Biosciences, Brussels, Belgium;111. Laboratoires Servier, Paris, France;112. University Hospitals Leuven, Leuven, Belgium;113. UPMC Hillman Cancer Center, Pittsburgh, PA, USA
Abstract:
Keywords:Correspondence to: Dr Fernando Ulloa-Montoya   GlaxoSmithKline   Rixensart   B1330 Belgium
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号